ESTRO 2025 - Abstract Book

S1112

Clinical – Head & neck

ESTRO 2025

4047

Digital Poster treatment outcomes of intra-arterial chemoradiotherapy for locally advanced tongue cancer Yutaka Toyomasu, Akinori Takada, Takamitsu Mase, Kazuki Omori, Akito Taniguchi, Tomoko Kawamura, Hajime Sakuma, Yoshihito Nomoto Radiology, Mie University Hospital, Tsu, Japan Purpose/Objective: This retrospective study aimed to evaluate the treatment outcomes in patients with locally advanced tongue cancer treated with intra-arterial chemoradiotherapy (IA-CRT) at a single institution. Material/Methods: Between June 2013 and September 2021, 25 patients with tongue cancer underwent IA-CRT. Intra-arterial chemotherapy regimen consisted of weekly cisplatin (35-50 mg/m 2 ) for 6 to 8 cycles. Patients were received curative radiotherapy (70 Gy in 35 fractions). Overall survival (OS), progression-free survival (PFS), local control (LC), and distant metastasis-free survival (DMFS) were calculated using the Kaplan-Meier method. The log-rank test and the Cox proportional hazards model were used for univariate and multivariate analyses, respectively. Results: Most patients presented with stage Ⅳ (n = 20, 80%). Twelve patients (48%) received induction chemotherapy. The median follow-up time was 53 months (range, 8-112 months). The 3-year OS, PFS, LC, and DMFS rates were 63%, 52%, 86%, and 59%, respectively. Thirteen (52%) of 25 patients were died. Disease recurrence occurred in 11 patients (37%): local recurrence in 3 patients (12%), regional recurrence in 6 patients (24%), and distant metastasis in 6 patients (24%). Grade 3 or greater late adverse events occurred in one patient (4%): osteonecrosis of the jaw (grade 3). In univariate analysis, induction chemotherapy was the significant prognostic factor for OS (p = 0.027), and N stage was for OS (p = 0.011) and PFS (p = 0.022). Conducting a multivariate analysis revealed that N2 disease was associated with worse OS (hazard ratio [HR] 5.172; 95% confidence interval [CI] 1.281-28.090, p=0.023) and PFS (HR 4.916; 95% CI, 1.079-22.390, p = 0.040).

Conclusion: IA-CRT offered excellent LC in the patients with locally advanced tongue cancer.

Keywords: tongue cancer, CRT, intra-arterial chemotherapy